Drugs / Belnacasan
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05164120 | Dec 2021 → Jul 2022 | COVID-19 | MedStar Health | Completed | No outcome recorded |
| Phase 2 | NCT01048255 | Jan → Nov 2010 | focal epilepsy | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT00205465 | Dec 2004 → Sep 2005 | psoriasis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01501383 Comparator | Dec 2011 → Aug 2013 | epilepsy | Vertex Pharmaceuticals Incorporated | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-03-10 | Vertex Pharmaceuticals Incorporated | Results Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment vrtx.com ↗
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a recently completed Phase 2 study of VX-765 in 60 people with treatment-resistant epilepsy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-03-10 | Vertex Pharmaceuticals Incorporated | Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment vrtx.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Belnacasan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05164120 ↗ |
| Known as | Belcanasan | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107819 ↗ |
| Known as | VX-765 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01501383 ↗ |
| Action | Inhibit | “Belnacasan prevents the activation of a particular enzyme, Caspase-1” NCT05164120 ↗1“Caspase-1 inhibitor” CHEMBL2107819 ↗ |
| Modality | Small molecule | — CHEMBL2107819 ↗ |
| Route | Oral | “300mg Oral Tablet” NCT01048255 ↗ |
| Target | CASP1 | “Caspase-1 inhibitor” CHEMBL2107819 ↗ |